The research did not have commercial funding, but patents for the vaccine have been licensed by the National Institutes of Health to Emergent BioSolutions. Two of Dr. Chen’s coauthors were employees of Emergent BioSolutions.
ad goes here:advert-1
SCROLL TO CONTINUE
- Chen GL, Coates EE, Plummer SH, et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: A randomized clinical trial. JAMA. 2020 Apr 14;323(14):1369–1377.
- Stapleford KA, Mulligan MJ. A new vaccine for Chikungunya virus. JAMA. 2020 Apr 14;323(14):1351–1352.